Table 2. Proportion of VTE and bleeding... | American Society of Hematology

Table 2.

Proportion of VTE and bleeding in pregnant women with essential thrombocythemia

	No LMWH	LMWH*
Antepartum period
VTE risk (%)	2.5 (95% CI, 1.3-4.3; I² 0%) (n = 407)	0.0 (95% CI, 0.0-5.7; I² 0%) (n = 82)
Bleeding risk† (%)	4.0 (95% CI, 1.5-7.8; I² 53.8%) (n = 407)	0.0 (95% CI, 0.0-5.7; I² 0%) (n = 82)
Postpartum period
VTE risk‡ (%)	4.4 (95% CI, 1.2-9.5; I² 48%) (n = 229)	0.0 (95% CI, 0.0-4.6; I² 0%) (n = 96)
Bleeding risk† (%)	2.9 (95% CI, 1.4-5.0; I² 0%) (n = 309)	2.9 (95% CI, 0.1-9.6; I² 0.1%) (n = 97)

	No LMWH	LMWH*
Antepartum period
VTE risk (%)	2.5 (95% CI, 1.3-4.3; I² 0%) (n = 407)	0.0 (95% CI, 0.0-5.7; I² 0%) (n = 82)
Bleeding risk† (%)	4.0 (95% CI, 1.5-7.8; I² 53.8%) (n = 407)	0.0 (95% CI, 0.0-5.7; I² 0%) (n = 82)
Postpartum period
VTE risk‡ (%)	4.4 (95% CI, 1.2-9.5; I² 48%) (n = 229)	0.0 (95% CI, 0.0-4.6; I² 0%) (n = 96)
Bleeding risk† (%)	2.9 (95% CI, 1.4-5.0; I² 0%) (n = 309)	2.9 (95% CI, 0.1-9.6; I² 0.1%) (n = 97)

LMWH use in the antepartum setting is defined as 4 weeks or more of LMWH use during pregnancy.

Including placental abruption.

Excluding first trimester losses.